Microfluidic Encapsulation of Exosomes Derived from Lipopolysaccharide‐Treated Mesenchymal Stem Cells in Hyaluronic Acid Methacryloyl to Restore Ovarian Function in Mice

Abstract Premature ovarian failure (POF) features an upward incidence nowadays, and the human umbilical cord mesenchymal stem cells (hUC‐MSCs)‐derived exosomes (MSC‐Exos) have shown applied values in the recovery of ovarian function. Here, a novel exosome‐encapsulated microcarrier prepared by microfluidic technology for ovarian repair after chemotherapy damage is presented. The exosomes derived from lipopolysaccharide (LPS)‐preconditioned hUC‐MSCs are encapsulated with hyaluronic acid methacryloyl (HAMA) via microfluidic electrospray, which is named HAMA/MSC‐Exos. Attributing to the biocompatibility and semipermeable property of HAMA, the encapsulated exosomes show great viability and controllable release behavior from HAMA. It is demonstrated that in situ transplantation of HAMA/MSC‐Exos can rescue ovarian functions of cyclophosphamide‐induced ovarian failure in mice by increasing ovarian volume, improving the number of antral follicles and restoring fertility. It is believed that the transplantation of HAMA/MSC‐Exos will provide a new concept for the treatment of POF in clinical practice.